Search for a trial

Cyclopentolate induced EEG changes in children

To compare the EEG pattern after administration of cyclopentolate with the EEG pattern after placebo eye-drops.Primary outcomeEEG pattern changes after administration of two drops of cyclopentolate1% compared with placebo.Secondary outcomes- Pattern…

Monosodium glutamate as a potential trigger for atrial fibrillation

To demonstrate the arrhythmogenic action of MSG in a single blinded placebo controlled test on these patients with reported MSG induced AF and to investigate the possibility of MSG as a potential trigger for AF.

A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once-Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients with an Implantable Cardioverter Defibrillator

This study (AZM-MD-302) will be undertaken to confirm the effectiveness of aonce-daily oral dose of 75 mg azimilide on the reduction of unplanned cardiovascular emergencydepartment visits and hospitalizations or cardiovascular death in patients with…

Effects of acute and chronic oral administration of S 44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1 - A randomized, parallel-group, international multicentre study including a 8-week double-blind placebo controlled period followed by a 8-week single-blind period - Phase II exploratory study

The objective of this study is to assess the effects of a single and chronic oral administration of S 44121 versus placebo on the occurrence of cardiac arrhythmia during standardized exercise tests (ETs) in patients with CPVT type 1. The safety…

A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centered Safety, Tolerability and Efficacy Study of RSD1235-SR to Prevent Atrial Fibrillation (AF) Recurrence in Subjects Post-Conversion

To evaluate the safety, tolerability and efficacy of 3 doses of vernakalant (oral) (150 mg, 300 mg and 500 mg b.i.d.) administered for up to 90 days in subjects with sustained symptomatic atrial fibrillation (AF duration > 72 hours and &…

A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrillation and additional risk factors

The primary objective of this trial is to demonstrate the efficacy of Dronedarone in preventing major cardiovascular events (stroke, systemic arterial embolism, myocardial infarction or cardiovascular death) or unplanned cardiovascular…

A Multi-center, Parallel-group, Double-blind, Placebo-controlled, Randomized, Ascending Dose Trial to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Infusions of OPC-108459 Administered to Subjects with Paroxysmal and Persistent Atrial Fibrillation.

Objective(s): Part 1: To determine the safety, tolerability, pharmacokinetics (PK), and efficacy of single ascending doses of OPC-108459 following one 10-minute constant rate infusion in adultsubjects diagnosed with paroxysmal or persistent AF. Part…

Safety, tolerability and sedative properties of single dose intranasal dexmedetomidine premedication in elderly subjects.

This study aims to evaluate the safety, tolerability and sedative proporties of a single dose of intransally administered dexmedetomidine in person odler than 65 years, differentiating between person using beta-blocking medication and those not…

A randomized, double blind, placebo-controlled, parallel, international multicenter study assessing the efficacy of S066913 in patients with paroxysmal atrial fibrillation.
Double-blind, International study AssessinG efficacy of S066913 in paRoxysmal Atrial Fibrillation -IKur inhibitor (DIAGRAF - IKUR)

The aim of this study is to evaluate the efficacy of three doses of S 066913 (5 mg, 25 mg and 100 mg o.d.) versus placebo administered for 4 weeks on atrial fibrillation and/or atrial tachycardia burden (AF/AT burden) in patients with paroxysmal…

A Phase 2, Double-Blind, Randomized, Placebo Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects with Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)

The primary objective of this study is as follows:* To evaluate the effect of GS-6615 compared to placebo on the overall occurrence of appropriate ICD interventions (antitachycardia pacing [ATP] or shock) in subjects with ICD or CRT-D during the…

A multi-center, Randomized, double-blind, placebo-controlled study to Evaluate the Safety and efficacy of a single oral dose of vanoxerine for The conversion Of subjects with REcent onset atrial fibrillation or flutter to normal Sinus Rhythm

To evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent atrial fibrillation (AF) or atrial flutter (AFL) to normal sinus rhythm.

APIXABAN FOR THE REDUCTION OF THROMBO-EMBOLISM IN PATIENTS
WITH DEVICE-DETECTED SUB-CLINICAL ATRIAL FIBRILLATION

To determine if the use of apixaban in patients with SCAF will reduce the incidence of stroke and systemic embolism compared to aspirin.

Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia;The RAPID Study (NODE-301 Part 2)

The primary objective of the RAPID study is to determine whether etripamil nasal spray (NS) self-administered by patients is superior to placebo at terminating episodes of PSVT in an at-home setting.The secondary objective of this study is to…

Multi-Centre, Placebo-Controlled, Phase 2 Study of Etripamil Nasal Spray (NS) for the Reduction of Ventricular Rate in Patients with Atrial Fibrillation

The primary objective of this study is to demonstrate the superiority of etripamil NS over placebo in reducing ventricular rate in patients with AF.

A Phase II, Double-Blind 2-arm study to investigate the effect on ventricular ectopy, safety, tolerability and pharmacokinetics of S48168 (ARM210) compared with Placebo in adults with Type 1 Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT1)

This is a research study. The purpose of this study is to test if the investigational medicinal product S48168 (ARM210) is safe and effective when given to patients diagnosed with CPVT1. Primairy objective:To assess the effect of S48168 (ARM210) on…

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Flecainide
Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation
to Sinus Rhythm

To compare the efficacy and safety of flecainide acetate inhalation solution to placebo for the conversion of atrial fibrillation (AF) to sinus rhythm (SR) in patients with recent-onset, symptomatic newly diagnosed or paroxysmal AF

Peri-operative Magnesium infusion to Prevent Atrial fibrillation Evaluated.

In patients undergoing cardiothoracic surgery, to investigate the effect of continuous (preceded by a bolus) administration of perioperative magnesium sulphate (MgSO4) on the incidence patients with POAF.

Extension of the randomized, double-blind, placebo-controlled single ascending dose study to assess the safety and tolerability of AP30663 in healthy subjects.

Primary ObjectivesTo evaluate the safety and tolerability of AP30663 in healthy males at doses up to 12mg/kgExploratory ObjectiveTo evaluate the effect of AP30663 on electrocardiographical parameters.

Multi-center, blinded, randomized, PaRAllEl-group, Phase 3 study with aproCItentan in Subjects with Resistant HypertensiON (RHT)

The primary objective of the study is to demonstrate the BP lowering effect ofaprocitentan when added to standard-of-care in true resistant hypertension subjects.The secondary objectives of the study are• to demonstrate that the effect of…

Randomized, double-blind, placebo-controlled single ascending dose study to assess the safety and tolerability of AP30663 in healthy subjects.

Primary Objective- To evaluate the safety and tolerability of AP30663 in healthy malesSecondary Objectives- To evaluate the pharmacokinetic profile of AP30663.Exploratory Objectives- To evaluate the effect of AP30663 on electrocardiographical…